Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ferric Carboxymaltose vs Injectafer in Iron Deficiency Anemia
NCT03399084Phase 1Completed
- Sponsor
- Sandoz
- Start
- Nov 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Sandoz. Primary endpoints: Maximum Serum Concentration of Serum Total Iron up to 7 days and Area Under the Serum Concentration-Time Curve of Serum Total Iron up to 7 days. Started Nov 2017; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03399084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03399084.